CpG-ODN combined with Neospora caninum lysate, but not with excreted-secreted antigen, enhances protection against infection in mice.
CpG oligodeoxynucleotides (ODN) have shown to be potent immunoadjuvants for several pathogens, but there is limited information concerning their use in immunization protocols against neosporosis. This study aimed to evaluate the potential of CpG-ODN combined with Neospora lysate antigen (NLA) or excreted-secreted antigen (NcESA) to induce protective immune response against Neospora caninum infection in mice. C57BL/6 mice were vaccinated subcutaneously three times at 2-week intervals with NLA, NLA+CpG, NcESA, NcESA+CpG, CpG (adjuvant control) or PBS (infection control). Serological assays showed an increased specific IgG2a response in animals immunized with either antigen plus adjuvant and elevated levels of the IgG1 isotype in those vaccinated with antigens alone. Splenocyte proliferative responses upon antigen stimulation were higher in groups immunized with NLA or NcESA combined with CpG, showing increased IL-12 levels. Also, mice vaccinated with NcESA or NcESA+CpG demonstrated higher IFN-gamma levels and IFN-gamma/IL-10 ratio. After lethal challenge, mice immunized with NLA+CpG or NLA had lower morbidity score and body weight changes in comparison to other groups, and animals did not succumb during acute infection. In contrast, NcESA+CpG or NcESA groups exhibited the highest morbidity scores, body weight impairment and mortality rates, associated with greatest brain parasite burden and inflammation. In conclusion, CpG-ODN was able to induce a Th1-type humoral immune response with predominant IgG2a levels for either NLA or NcESA, but resulting in an effective Th1-driven cellular immune response and total protection only when combined with NLA. Vaccination with NcESA alone or combined with CpG resulted in a strong cellular immune response associated with high levels of IFN-gamma and inflammation, rendering mice more susceptible to parasite challenge.
Laboratory of Immunoparasitology, Institute of Biomedical Sciences, Federal University of Uberlândia, Av. Pará 1720, Uberlândia 38400-902, MG, Brazil.
Dâmaso P
DP
Ribeiro
Marina M P
MM
Freitas
Mariana R D
MR
Cardoso
Ana C A M
AC
Pajuaba
Neide M
NM
Silva
Tiago W P
TW
Mineo
João S
JS
Silva
José R
JR
Mineo
Deise A O
DA
Silva
D000818:Animals; D000908:Antibodies, Fungal / Q000097:blood; D000946:Antigens, Fungal / Q000276:immunology*; D001835:Body Weight; D001921:Brain / Q000382:microbiology / Q000473:pathology; D049109:Cell Proliferation; D003048:Coccidiosis / Q000517:prevention & control*; D016207:Cytokines / Q000378:metabolism; D005657:Fungal Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood; D007279:Injections, Subcutaneous; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018688:Neospora / Q000276:immunology*; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage / Q000494:pharmacology*; D012720:Severity of Illness Index; D013154:Spleen / Q000276:immunology; D016019:Survival Analysis; D022223:Vaccines, Subunit / Q000276:immunology
D000908:Antibodies, Fungal; D000946:Antigens, Fungal; C408982:CPG-oligonucleotide; D016207:Cytokines; D005657:Fungal Vaccines; D007074:Immunoglobulin G; D009838:Oligodeoxyribonucleotides; D022223:Vaccines, Subunit